Kallikrein 11 antibody (AA 68-82)

Catalog No. ABIN636296

Product Details anti-Kallikrein 11 Antibody

Target: Kallikrein 11 (KLK11)

Binding Specificity: AA 68-82

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Kallikrein 11 antibody is un-conjugated

Application: Western Blotting (WB)

Cross-Reactivity: Mouse (Murine), Rat (Rattus)

Cross-Reactivity (Details): This antibodys immunogen shares 86 % sequence identity with the Mouse, and rat homologs.

Purification: Affinity chromatography purified

Immunogen: KLK11 antibody was raised in rabbit using AA 68-82 [YIVHLGQHNLQKEEG] of the 35 kDa human hippostasin/KLK11 protein as the immunogen.

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Target Details for Kallikrein 11

Target: Kallikrein 11 (KLK11)

Alternative Name: KLK11 (KLK11 Products)

Synonyms: KLK11 antibody, 2310015I08Rik antibody, Prss20 antibody, TLSP antibody, PRSS20 antibody, kallikrein related peptidase 11 antibody, kallikrein related-peptidase 11 antibody, kallikrein-related peptidase 11 antibody, KLK11 antibody, Klk11 antibody

Background: Hippostasin, also known as KLK11, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type. Hippostasin plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of hK11 were found in 70% of women with ovarian cancer and in 60% of men with prostate cancer.

Pathways: Complement System